Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (5): 775-780. doi: 10.19723/j.issn.1671-167X.2023.05.002
Previous Articles Next Articles
蔚 薛*(
),樑 董,宏阳 钱,笑晨 费
CLC Number:
- R737.25
| 1 |
ChenR , RenS , Chinese Prostate Cancer Consortium ,et al.Prostate cancer in Asia: A collaborative report[J].Asian J Urol,2014,1(1):15-29.
doi: 10.1016/j.ajur.2014.08.007 |
| 2 |
ManoR , EasthamJ , YossepowitchO .The very-high-risk prostate cancer: A contemporary update[J].Prostate Cancer Prostatic Dis,2016,19(4):340-348.
doi: 10.1038/pcan.2016.40 |
| 3 |
ShelleyMD , KumarS , WiltT ,et al.A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma[J].Cancer Treat Rev,2009,35(1):9-17.
doi: 10.1016/j.ctrv.2008.08.002 |
| 4 | KumarS , ShelleyM , HarrisonC ,et al.Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer[J].Cochrane Database Syst Rev,2006,(4):CD006019. |
| 5 |
O'DonnellA , JudsonI , DowsettM ,et al.Hormonal impact of the 17alpha-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer[J].Br J Cancer,2004,90(12):2317-2325.
doi: 10.1038/sj.bjc.6601879 |
| 6 |
TaplinME , MontgomeryB , LogothetisCJ ,et al.Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: Results of a randomized phase Ⅱ neoadjuvant study[J].J Clin Oncol,2014,32(33):3705-3715.
doi: 10.1200/JCO.2013.53.4578 |
| 7 |
EfstathiouE , DavisJW , PistersL ,et al.Clinical and biological characterisation of localised high-risk prostate cancer: Results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone[J].Eur Urol,2019,76(4):418-424.
doi: 10.1016/j.eururo.2019.05.010 |
| 8 |
MontgomeryB , TretiakovaMS , JoshuaAM ,et al.Neoadjuvant enzalutamide prior to prostatectomy[J].Clin Cancer Res,2017,23(9):2169-2176.
doi: 10.1158/1078-0432.CCR-16-1357 |
| 9 |
YangX , AllenJC , AslimEJ ,et al.Patient-reported outcomes of a phase Ⅱ neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial[J].Int J Urol,2022,29(11):1322-1330.
doi: 10.1111/iju.14994 |
| 10 |
DevosG , ToscoL , BaldewijnsM ,et al.ARNEO: A randomized phase Ⅱ trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer[J].Eur Urol,2023,83(6):508-518.
doi: 10.1016/j.eururo.2022.09.009 |
| 11 |
MckayRR , YeH , XieW ,et al.Evaluation of intense androgen deprivation before prostatectomy: A randomized phase Ⅱ trial of enzalutamide and leuprolide with or without abiraterone[J].J Clin Oncol,2019,37(11):923-931.
doi: 10.1200/JCO.18.01777 |
| 12 |
EfstathiouE , BoukovalaM , SpetsierisN ,et al.Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC)[J].J Clin Oncol,2020,38,5504.
doi: 10.1200/JCO.2020.38.15_suppl.5504 |
| 13 |
MckayRR , XieW , YeH ,et al.Results of a randomized phase Ⅱ trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer[J].J Urol,2021,206(1):80-87.
doi: 10.1097/JU.0000000000001702 |
| 14 |
SweeneyCJ , ChenYH , CarducciM ,et al.Chemohormonal therapy in metastatic hormone-sensitive prostate cancer[J].N Engl J Med,2015,373(8):737-746.
doi: 10.1056/NEJMoa1503747 |
| 15 |
JamesND , SydesMR , ClarkeNW ,et al.Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial[J].Lancet,2016,387(10024):1163-1177.
doi: 10.1016/S0140-6736(15)01037-5 |
| 16 |
PanJ , ChiC , QianH ,et al.Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study[J].Urol Oncol,2019,37(12):991-998.
doi: 10.1016/j.urolonc.2019.07.009 |
| 17 |
DreicerR , Magi-GalluzziC , ZhouM ,et al.Phase Ⅱ trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate can-cer[J].Urology,2004,63(6):1138-1142.
doi: 10.1016/j.urology.2004.01.040 |
| 18 | MikkilineniN , HyamsES .Neoadjuvant therapies for surgical management of high-risk, localized prostate cancer[J].Transl Cancer Res,2018,7(Suppl 6):S662-S675. |
| 19 |
FizaziK , FaivreL , LesaunierF ,et al.Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): A phase 3 randomised controlled trial[J].Lancet Oncol,2015,16(7):787-794.
doi: 10.1016/S1470-2045(15)00011-X |
| 20 |
潘家骅, 刘家舟, 王勇,等.新辅助内分泌治疗联合化疗对极高危局部进展期前列腺癌疗效的多中心临床分析[J].中华泌尿外科杂志,2021,42(9):685-690.
doi: 10.3760/cma.j.cn112330-20210819-00436 |
| 21 |
GlicksmanR , SanmamedN , ThomsJ ,et al.A phase 1 pilot study of preoperative radiation therapy for prostate cancer: Long-term toxicity and oncologic outcomes[J].Int J Radiat Oncol Biol Phys,2019,104(1):61-66.
doi: 10.1016/j.ijrobp.2018.12.054 |
| 22 |
SartorO , de BonoJ , ChiKN ,et al.Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer[J].N Engl J Med,2021,385(12):1091-1103.
doi: 10.1056/NEJMoa2107322 |
| 23 |
GolanS , FrumerM , ZoharY ,et al.Neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: A single-arm phase 1 trial[J].Eur Urol Oncol,2023,6(2):151-159.
doi: 10.1016/j.euo.2022.09.002 |
| 24 | HanksGE .External-beam radiation therapy for clinically localized prostate cancer: Patterns of care studies in the United States[J].NCI Monogr,1988,(7):75-84. |
| 25 |
AusG , NordenskjoldK , RobinsonD ,et al.Prognostic factors and survival in node-positive (N1) prostate cancer: A prospective study based on data from a Swedish population-based cohort[J].Eur Urol,2003,43(6):627-631.
doi: 10.1016/S0302-2838(03)00156-8 |
| 26 |
PassoniNM , FajkovicH , XylinasE ,et al.Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: Value of extranodal extension and size of the largest LN metastasis[J].BJU Int,2014,114(4):503-510.
doi: 10.1111/bju.12342 |
| 27 | DaneshmandS , QuekML , SteinJP ,et al.Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: Long-term results[J].J Urol,2004,172(6 Pt 1):2252-2255. |
| 28 |
WiegelT , BartkowiakD , BottkeD ,et al.Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial[J].Eur Urol,2014,66(2):243-250.
doi: 10.1016/j.eururo.2014.03.011 |
| 29 |
ThompsonIM , TangenCM , ParadeloJ ,et al.Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial[J].J Urol,2009,181(3):956-962.
doi: 10.1016/j.juro.2008.11.032 |
| 30 |
BollaM , van PoppelH , TombalB ,et al.Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911)[J].Lancet,2012,380(9858):2018-2027.
doi: 10.1016/S0140-6736(12)61253-7 |
| 31 |
HackmanG , TaariK , TammelaTL ,et al.Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension[J].Eur Urol,2019,76(5):586-595.
doi: 10.1016/j.eururo.2019.07.001 |
| 32 |
GhavamianR , BergstralhEJ , BluteML ,et al.Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: A matched comparison[J].J Urol,1999,161(4):1223-1227.
doi: 10.1016/S0022-5347(01)61640-9 |
| 33 |
MessingEM , ManolaJ , YaoJ ,et al.Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy[J].Lancet Oncol,2006,7(6):472-479.
doi: 10.1016/S1470-2045(06)70700-8 |
| 34 |
AbdollahF , KarnesRJ , SuardiN ,et al.Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer[J].J Clin Oncol,2014,32(35):3939-3947.
doi: 10.1200/JCO.2013.54.7893 |
| 35 |
LowranceW , DreicerR , JarrardDF ,et al.Updates to advanced prostate cancer: AUA/SUO guideline (2023)[J].J Urol,2023,209(6):1082-1090.
doi: 10.1097/JU.0000000000003452 |
| 36 |
RoachPJ , FrancisR , EmmettL ,et al.The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an Australian prospective multicenter study[J].J Nucl Med,2018,59(1):82-88.
doi: 10.2967/jnumed.117.197160 |
| 37 |
YaxleyJW , RaveenthiranS , NouhaudF X ,et al.Risk of metastatic disease on 68gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1 253 men at the diagnosis of prostate cancer[J].BJU Int,2019,124(3):401-407.
doi: 10.1111/bju.14828 |
| 38 |
HofmanMS , LawrentschukN , FrancisRJ ,et al.Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study[J].Lancet,2020,395(10231):1208-1216.
doi: 10.1016/S0140-6736(20)30314-7 |
| [1] | Zhicun LI, Tianyu WU, Lei LIANG, Yu FAN, Yisen MENG, Qian ZHANG. Risk factors analysis and nomogram model construction of postoperative pathological upgrade of prostate cancer patients with single core positive biopsy [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 896-901. |
| [2] | 教悌 黄,菁 胡,博 韩. [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 557-561. |
| [3] | 念增 邢,明帅 王,飞亚 杨,路 尹,苏军 韩. [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 565-566. |
| [4] | Yuxuan TIAN,Mingjian RUAN,Yi LIU,Derun LI,Jingyun WU,Qi SHEN,Yu FAN,Jie JIN. Predictive effect of the dual-parametric MRI modified maximum diameter of the lesions with PI-RADS 4 and 5 on the clinically significant prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 567-574. |
| [5] | Kaifeng YAO,Mingjian RUAN,Derun LI,Yuxuan TIAN,Yuke CHEN,Yu FAN,Yi LIU. Diagnostic efficacy of targeted biopsy combined with regional systematic biopsy in prostate cancer in patients with PI-RADS 4-5 [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 575-581. |
| [6] | Ye YAN,Xiaolong LI,Haizhui XIA,Xuehua ZHU,Yuting ZHANG,Fan ZHANG,Ke LIU,Cheng LIU,Lulin MA. Analysis of risk factors for long-term overactive bladder after radical prostatectomy [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 589-593. |
| [7] | Shuhui YU,Jianing HAN,Lijun ZHONG,Congyu CHEN,Yunxiang XIAO,Yanbo HUANG,Yang YANG,Xinyan CHE. Predictive value of preoperative pelvic floor electrophysiological parameters on early urinary incontinence following radical prostatectomy [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 594-599. |
| [8] | Yi LIU,Chang-wei YUAN,Jing-yun WU,Qi SHEN,Jiang-xi XIAO,Zheng ZHAO,Xiao-ying WANG,Xue-song LI,Zhi-song HE,Li-qun ZHOU. Diagnostic efficacy of prostate cancer using targeted biopsy with 6-core systematic biopsy for patients with PI-RADS 5 [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 812-817. |
| [9] | Hai MAO,Fan ZHANG,Zhan-yi ZHANG,Ye YAN,Yi-chang HAO,Yi HUANG,Lu-lin MA,Hong-ling CHU,Shu-dong ZHANG. Predictive model of early urinary continence recovery based on prostate gland MRI parameters after laparoscopic radical prostatectomy [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 818-824. |
| [10] | Chang-wei YUAN,De-run LI,Zhi-hua LI,Yi LIU,Gang-zhi SHAN,Xue-song LI,Li-qun ZHOU. Application of dynamic contrast enhanced status in multiparametric magnetic resonance imaging for prostatic cancer with PI-RADS 4 lesion [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 838-842. |
| [11] | ZHANG Fan,CHEN Qu,HAO Yi-chang,YAN Ye,LIU Cheng,HUANG Yi,MA Lu-lin. Relationship between recovery of urinary continence after laparoscopic radical prostatectomy and preoperative/postoperative membranous urethral length [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 299-303. |
| [12] | ZHANG Fan,HUANG Xiao-juan,YANG Bin,YAN Ye,LIU Cheng,ZHANG Shu-dong,HUANG Yi,MA Lu-lin. Relationship between prostate apex depth and early recovery of urinary continence after laparoscopic radical prostatectomy [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 692-696. |
| [13] | HAO Han,LIU Yue,CHEN Yu-ke,SI Long-mei,ZHANG Meng,FAN Yu,ZHANG Zhong-yuan,TANG Qi,ZHANG Lei,WU Shi-liang,SONG Yi,LIN Jian,ZHAO Zheng,SHEN Cheng,YU Wei,HAN Wen-ke. Evaluating continence recovery time after robot-assisted radical prostatectomy [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 697-703. |
| [14] | Yi LIU,Zhi-jian LIU,Qi SHEN,Jing-yun WU,Yu FAN,De-run LI,Wei YU,Zhi-song HE. A clinical analysis of 14 cases of prostatic stromal tumor of uncertain malignant potential [J]. Journal of Peking University (Health Sciences), 2020, 52(4): 621-624. |
| [15] | Yi-chang HAO,Ye YAN,Fan ZHANG,Min QIU,Lang ZHOU,Ke LIU,Jian LU,Chun-lei XIAO,Yi HUANG,Cheng LIU,Lu-lin MA. Surgical strategy selection and experience summary of prostate cancer with positive single needle biopsy [J]. Journal of Peking University (Health Sciences), 2020, 52(4): 625-631. |
|
||